Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 3Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 7INDUSTRY 4NIH 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Plasma cell 7

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, B-Cell 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 12Recurrence 11Burkitt Lymphoma 10Multiple Myeloma 7Lymphoma 7Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Leukemia 5Pancreatic Neoplasms 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Leukemia, B-Cell 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Simpson-Golabi-Behmel syndrome 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Immunotherapy, Adoptive × Clear all
NCT07612787 2026-05-29

BELAMI

Centre Hospitalier Universitaire de Saint Etienne

Phase 2 Not yet recruiting
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07458659 2026-03-09

CART-BCMA

Chulalongkorn University

Phase EARLY_PHASE1 Not yet recruiting
3 enrolled
Plasma cell

Multiple Myeloma

NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03271632 2019-09-19

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Unknown
20 enrolled
Plasma cell

Multiple Myeloma

NCT01886976 2016-01-28

CART-138

Chinese PLA General Hospital

Phase 1/2 Unknown
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡